Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1993 Sep;92(3):1296–1301. doi: 10.1172/JCI116703

The HLA-DR and DQ genes control the autoimmune response to DNA topoisomerase I in systemic sclerosis (scleroderma).

M Kuwana 1, J Kaburaki 1, Y Okano 1, H Inoko 1, K Tsuji 1
PMCID: PMC288271  PMID: 7690776

Abstract

HLA class II alleles were determined using the PCR-RFLP method in Japanese systemic sclerosis (scleroderma) patients with (n = 28) or without (n = 34) anti-topoisomerase I antibodies (anti-topo I). Either the DQB1*0601 or *0301 allele was recognized in all anti-topo I positive patients, compared with 44% of anti-topo I negative patients (P < 0.00001, relative risk [RR] > 41) or 58% of Japanese healthy control subjects (P < 0.00001, RR > 24). Tyrosine at position 26 in the second hypervariable region in the beta 1 domain of the DQB1 gene is common to these two alleles and is not present in any other known DQB1 alleles. We also examined immunoreactivities of anti-topo I positive sera to four different autoantigenic B cell epitopes of topo I molecule that were expressed as recombinant fusion proteins. One major B cell epitope, located within the region corresponding to amino acid residues 74-248, was perfectly associated with the amino acid sequence FLEDR at positions 67-71 in the beta 1 domain of the DRB gene. Two other epitopes, corresponding to 316-441 or 658-700, were associated with the serologically defined HLA-DR52 antigen. Patients with both FLEDR and DR52 demonstrated higher anti-topo I antibody titers. These results suggest that the HLA-DR and DQ genes together control the autoimmune response to topo I in systemic sclerosis.

Full text

PDF
1296

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alarcón G. S., Phillips R. M., Wasner C. K., Acton R. T., Barger B. O. DR antigens in systemic sclerosis: lack of clinical correlations. Tissue Antigens. 1985 Aug;26(2):156–158. doi: 10.1111/j.1399-0039.1985.tb00950.x. [DOI] [PubMed] [Google Scholar]
  2. Babbitt B. P., Allen P. M., Matsueda G., Haber E., Unanue E. R. Binding of immunogenic peptides to Ia histocompatibility molecules. 1985 Sep 26-Oct 2Nature. 317(6035):359–361. doi: 10.1038/317359a0. [DOI] [PubMed] [Google Scholar]
  3. Birnbaum N. S., Rodnan G. P., Rabin B. S., Bassion S. Histocompatibility antigens in progressive systemic sclerosis (scleroderma). J Rheumatol. 1977 Winter;4(4):425–428. [PubMed] [Google Scholar]
  4. Black C. M., Welsh K. I., Maddison P. J., Jayson M. I., Bernstein R. M. HLA antigens, autoantibodies and clinical subsets in scleroderma. Br J Rheumatol. 1984 Nov;23(4):267–271. doi: 10.1093/rheumatology/23.4.267. [DOI] [PubMed] [Google Scholar]
  5. Briggs D. C., Welsh K., Pereira R. S., Black C. M. A strong association between null alleles at the C4A locus in the major histocompatibility complex and systemic sclerosis. Arthritis Rheum. 1986 Oct;29(10):1274–1277. doi: 10.1002/art.1780291014. [DOI] [PubMed] [Google Scholar]
  6. Brown J. H., Jardetzky T., Saper M. A., Samraoui B., Bjorkman P. J., Wiley D. C. A hypothetical model of the foreign antigen binding site of class II histocompatibility molecules. Nature. 1988 Apr 28;332(6167):845–850. doi: 10.1038/332845a0. [DOI] [PubMed] [Google Scholar]
  7. Buus S., Colon S., Smith C., Freed J. H., Miles C., Grey H. M. Interaction between a "processed" ovalbumin peptide and Ia molecules. Proc Natl Acad Sci U S A. 1986 Jun;83(11):3968–3971. doi: 10.1073/pnas.83.11.3968. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Clements P. J., Opelz G., Terasaki P. I., Mickey M. R., Furst D. Association of HLA antigen a9 with progressive systemic sclerosis (scleroderma). Tissue Antigens. 1978 Apr;11(4):357–361. doi: 10.1111/j.1399-0039.1978.tb01268.x. [DOI] [PubMed] [Google Scholar]
  9. D'Arpa P., White-Cooper H., Cleveland D. W., Rothfield N. F., Earnshaw W. C. Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients. Arthritis Rheum. 1990 Oct;33(10):1501–1511. doi: 10.1002/art.1780331007. [DOI] [PubMed] [Google Scholar]
  10. DiBartolomeo A. G., Rabin B. S., Rodnan G. P. HLA-D antigens in progressive systemic sclerosis (scleroderma). Immunol Commun. 1981;10(8):733–740. doi: 10.3109/08820138109051959. [DOI] [PubMed] [Google Scholar]
  11. Dunckley H., Jazwinska E. C., Gatenby P. A., Serjeantson S. W. DNA-DR typing shows HLA-DRw11 RFLPs are increased in frequency in both progressive systemic sclerosis and CREST variants of scleroderma. Tissue Antigens. 1989 Mar;33(3):418–420. doi: 10.1111/j.1399-0039.1989.tb01686.x. [DOI] [PubMed] [Google Scholar]
  12. Ercilla M. G., Arriaga F., Gratacós M. R., Coll J., Lecha V., Vives J., Castillo R. HLA antigens and scleroderma. Arch Dermatol Res. 1981;271(4):381–385. doi: 10.1007/BF00406682. [DOI] [PubMed] [Google Scholar]
  13. Fritzler M. J., Kinsella T. D. The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med. 1980 Oct;69(4):520–526. doi: 10.1016/0002-9343(80)90462-3. [DOI] [PubMed] [Google Scholar]
  14. Genth E., Mierau R., Genetzky P., von Mühlen C. A., Kaufmann S., von Wilmowsky H., Meurer M., Krieg T., Pollmann H. J., Hartl P. W. Immunogenetic associations of scleroderma-related antinuclear antibodies. Arthritis Rheum. 1990 May;33(5):657–665. doi: 10.1002/art.1780330508. [DOI] [PubMed] [Google Scholar]
  15. Germain B. F., Espinoza L. R., Bergen L. L., Vagesh M., Vasey F. B. Increased prevalence of DRw3 in the CREST syndrome. Arthritis Rheum. 1981 Jun;24(6):857–859. doi: 10.1002/art.1780240615. [DOI] [PubMed] [Google Scholar]
  16. Gladman D. D., Keystone E. C., Baron M., Lee P., Cane D., Mervert H. Increased frequency of HLA-DR5 in scleroderma. Arthritis Rheum. 1981 Jun;24(6):854–856. doi: 10.1002/art.1780240614. [DOI] [PubMed] [Google Scholar]
  17. Hirayama K., Matsushita S., Kikuchi I., Iuchi M., Ohta N., Sasazuki T. HLA-DQ is epistatic to HLA-DR in controlling the immune response to schistosomal antigen in humans. Nature. 1987 Jun 4;327(6121):426–430. doi: 10.1038/327426a0. [DOI] [PubMed] [Google Scholar]
  18. Hughes P., Gelsthorpe K., Doughty R. W., Rowell N. R., Rosenthal F. D., Sneddon I. B. The association of HLA-B8 with visceral disease in systemic sclerosis. Clin Exp Immunol. 1978 Mar;31(3):351–356. [PMC free article] [PubMed] [Google Scholar]
  19. Inoko H., Ando A., Ito M., Tsuji K. Southern hybridization analysis of DNA polymorphism in the HLA-D region. Hum Immunol. 1986 Jul;16(3):304–313. doi: 10.1016/0198-8859(86)90058-3. [DOI] [PubMed] [Google Scholar]
  20. Kallenberg C. G., Van der Voort-Beelen J. M., D'Amaro J., The T. H. Increased frequency of B8/DR3 in scleroderma and association of the haplotype with impaired cellular immune response. Clin Exp Immunol. 1981 Mar;43(3):478–485. [PMC free article] [PubMed] [Google Scholar]
  21. Kamikawaji N., Fujisawa K., Yoshizumi H., Fukunaga M., Yasunami M., Kimura A., Nishimura Y., Sasazuki T. HLA-DQ-restricted CD4+ T cells specific to streptococcal antigen present in low but not in high responders. J Immunol. 1991 Apr 15;146(8):2560–2567. [PubMed] [Google Scholar]
  22. Livingston J. Z., Scott T. E., Wigley F. M., Anhalt G. J., Bias W. B., McLean R. H., Hochberg M. C. Systemic sclerosis (scleroderma): clinical, genetic, and serologic subsets. J Rheumatol. 1987 Jun;14(3):512–518. [PubMed] [Google Scholar]
  23. Lynch C. J., Singh G., Whiteside T. L., Rodnan G. P., Medsger T. A., Jr, Rabin B. S. Histocompatibility antigens in progressive systemic sclerosis (PSS; scleroderma). J Clin Immunol. 1982 Oct;2(4):314–318. doi: 10.1007/BF00915073. [DOI] [PubMed] [Google Scholar]
  24. Maul G. G., Jimenez S. A., Riggs E., Ziemnicka-Kotula D. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I: sequence similarity with retroviral p30gag protein suggests a possible cause for autoimmunity in systemic sclerosis. Proc Natl Acad Sci U S A. 1989 Nov;86(21):8492–8496. doi: 10.1073/pnas.86.21.8492. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Mollenhauer E., Schmidt R., Heinrichs M., Rittner C. Scleroderma: possible significance of silent alleles at the C4B locus. Arthritis Rheum. 1984 Jun;27(6):711–712. doi: 10.1002/art.1780270619. [DOI] [PubMed] [Google Scholar]
  26. Naruse T., Nose Y., Tsuji K., Inoko H. Strong and unique associations of HLA-DPB1 alleles with other HLA antigens in a Japanese population. Tissue Antigens. 1992 May;39(5):276–279. doi: 10.1111/j.1399-0039.1992.tb01948.x. [DOI] [PubMed] [Google Scholar]
  27. Niks M., Rovenský J., Nyulassy S., Buc M., Stefanovic J., Zitnan D. Lack of association of HLA-DR antigens with progressive systemic sclerosis (scleroderma). Tissue Antigens. 1982 Mar;19(3):238–239. doi: 10.1111/j.1399-0039.1982.tb01446.x. [DOI] [PubMed] [Google Scholar]
  28. Nishikai M., Okano Y., Yamashita H., Watanabe M. Characterisation of centromere (kinetochore) antigen reactive with sera of patients with a scleroderma variant (CREST syndrome). Ann Rheum Dis. 1984 Dec;43(6):819–824. doi: 10.1136/ard.43.6.819. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Nishimura Y., Sasazuki T. Suppressor T cells control the HLA-linked low responsiveness to streptococcal antigen in man. Nature. 1983 Mar 3;302(5903):67–69. doi: 10.1038/302067a0. [DOI] [PubMed] [Google Scholar]
  30. Nomura N., Ota M., Tsuji K., Inoko H. HLA-DQB1 genotyping by a modified PCR-RFLP method combined with group-specific primers. Tissue Antigens. 1991 Aug;38(2):53–59. doi: 10.1111/j.1399-0039.1991.tb01881.x. [DOI] [PubMed] [Google Scholar]
  31. Ota M., Seki T., Fukushima H., Tsuji K., Inoko H. HLA-DRB1 genotyping by modified PCR-RFLP method combined with group-specific primers. Tissue Antigens. 1992 Apr;39(4):187–202. doi: 10.1111/j.1399-0039.1992.tb01935.x. [DOI] [PubMed] [Google Scholar]
  32. Ota M., Seki T., Nomura N., Sugimura K., Mizuki N., Fukushima H., Tsuji K., Inoko H. Modified PCR-RFLP method for HLA-DPB1 and -DQA1 genotyping. Tissue Antigens. 1991 Aug;38(2):60–71. doi: 10.1111/j.1399-0039.1991.tb01882.x. [DOI] [PubMed] [Google Scholar]
  33. Piccinini G., Cardellini E., Reimer G., Arnett F. C., Durban E. An antigenic region of topoisomerase I in DNA polymerase chain reaction-generated fragments recognized by autoantibodies of scleroderma patients. Mol Immunol. 1991 Apr-May;28(4-5):333–339. doi: 10.1016/0161-5890(91)90145-a. [DOI] [PubMed] [Google Scholar]
  34. Reveille J. D., Durban E., MacLeod-St Clair M. J., Goldstein R., Moreda R., Altman R. D., Arnett F. C. Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis). J Clin Invest. 1992 Sep;90(3):973–980. doi: 10.1172/JCI115974. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Reveille J. D., Owerbach D., Goldstein R., Moreda R., Isern R. A., Arnett F. C. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). J Clin Invest. 1992 Apr;89(4):1208–1213. doi: 10.1172/JCI115704. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Sasazuki T., Kaneoka H., Nishimura Y., Kaneoka R., Hayama M., Ohkuni H. An HLA-linked immune suppression gene in man. J Exp Med. 1980 Aug 1;152(2 Pt 2):297s–313s. [PubMed] [Google Scholar]
  37. Sasazuki T., Kohno Y., Iwamoto I., Tanimura M., Naito S. Association between an HLA haplotype and low responsiveness to tetanus toxoid in man. Nature. 1978 Mar 23;272(5651):359–361. doi: 10.1038/272359b0. [DOI] [PubMed] [Google Scholar]
  38. Steen V. D., Powell D. L., Medsger T. A., Jr Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum. 1988 Feb;31(2):196–203. doi: 10.1002/art.1780310207. [DOI] [PubMed] [Google Scholar]
  39. Steen V. D., Ziegler G. L., Rodnan G. P., Medsger T. A., Jr Clinical and laboratory associations of anticentromere antibody in patients with progressive systemic sclerosis. Arthritis Rheum. 1984 Feb;27(2):125–131. doi: 10.1002/art.1780270202. [DOI] [PubMed] [Google Scholar]
  40. Tan E. M., Rodnan G. P., Garcia I., Moroi Y., Fritzler M. J., Peebles C. Diversity of antinuclear antibodies in progressive systemic sclerosis. Anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum. 1980 Jun;23(6):617–625. doi: 10.1002/art.1780230602. [DOI] [PubMed] [Google Scholar]
  41. Terasaki P. I., Bernoco D., Park M. S., Ozturk G., Iwaki Y. Microdroplet testing for HLA-A, -B, -C, and -D antigens. The Phillip Levine Award Lecture. Am J Clin Pathol. 1978 Feb;69(2):103–120. doi: 10.1093/ajcp/69.2.103. [DOI] [PubMed] [Google Scholar]
  42. Uryu N., Maeda M., Ota M., Tsuji K., Inoko H. A simple and rapid method for HLA-DRB and -DQB typing by digestion of PCR-amplified DNA with allele specific restriction endonucleases. Tissue Antigens. 1990 Jan;35(1):20–31. doi: 10.1111/j.1399-0039.1990.tb01751.x. [DOI] [PubMed] [Google Scholar]
  43. Verheijen R., Van den Hoogen F., Beijer R., Richter A., Penner E., Habets W. J., van Venrooij W. J. A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis. Clin Exp Immunol. 1990 Apr;80(1):38–43. doi: 10.1111/j.1365-2249.1990.tb06438.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  44. Weiner E. S., Earnshaw W. C., Senécal J. L., Bordwell B., Johnson P., Rothfield N. F. Clinical associations of anticentromere antibodies and antibodies to topoisomerase I. A study of 355 patients. Arthritis Rheum. 1988 Mar;31(3):378–385. doi: 10.1002/art.1780310309. [DOI] [PubMed] [Google Scholar]
  45. Whiteside T. L., Medsger T. A., Jr, Rodnan G. P. HLA-DR antigens in progressive systemic sclerosis (scleroderma). J Rheumatol. 1983 Feb;10(1):128–131. [PubMed] [Google Scholar]
  46. Yoshida S., Akizuki M., Mimori T., Yamagata H., Inada S., Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983 May;26(5):604–611. doi: 10.1002/art.1780260505. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES